Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals
Arrowhead granted Madrigal an exclusive global license for ARO-PNPLA3, receiving $25 million upfront and eligibility for up to $975 million in milestones plus tiered royalties. Phase 1 data published in The New England Journal of Medicine showed a 46% reduction in liver fat for homozygous patients with the PNPLA3 I148M mutation, with no clinically meaningful adverse events.
Key figures
- Phase 1 patients n
- 64
- Upfront payment usd
- 25000000
- Liver fat reduction pct
- 46
- Potential milestone usd
- 975000000
- Homozygous patients liver fat reduction
- 46
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.